Clinical relevance of tertiary lymphoid structures in esophageal squamous cell carcinoma.
B cell
Chemotherapy
Esophageal squamous cell carcinoma
Immunotherapy
Tertiary lymphoid structures
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
24 Jun 2022
24 Jun 2022
Historique:
received:
22
03
2022
accepted:
15
06
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
29
6
2022
Statut:
epublish
Résumé
Tertiary lymphoid structures (TLSs) have been reported to be involved in immune responses in many carcinomas. This study investigated the significance of TLSs in esophageal squamous cell carcinoma, focusing on TLS maturation. METHODS: The relationships of TLSs with clinicopathological features of 236 patients who underwent curative surgery for stage 0-IV esophageal squamous cell carcinoma were investigated. Mature TLSs, in which the germinal center formation was rich in CD23 TLSs were located mainly at the invasive margin of the tumor in cases with esophageal squamous cell carcinoma. Among the patients treated with neoadjuvant chemotherapy, those with advanced disease had a better prognosis in the GC-TLS high-density group than did those in the GC-TLS low-density group. Patients in whom neoadjuvant chemotherapy was effective had more GC-TLSs than those in whom it was less effective. The density of GC-TLSs and the number of tumor-infiltrating CD8 TLS maturation may be important for evaluating the local tumor immune response in patients treated with neoadjuvant chemotherapy for esophageal squamous cell carcinoma. The present results suggest that TLS maturation may be a useful target for predicting the efficacy of immunotherapy, including immune checkpoint inhibitor treatment for esophageal squamous cell carcinoma.
Sections du résumé
BACKGROUND
BACKGROUND
Tertiary lymphoid structures (TLSs) have been reported to be involved in immune responses in many carcinomas. This study investigated the significance of TLSs in esophageal squamous cell carcinoma, focusing on TLS maturation. METHODS: The relationships of TLSs with clinicopathological features of 236 patients who underwent curative surgery for stage 0-IV esophageal squamous cell carcinoma were investigated. Mature TLSs, in which the germinal center formation was rich in CD23
RESULTS
RESULTS
TLSs were located mainly at the invasive margin of the tumor in cases with esophageal squamous cell carcinoma. Among the patients treated with neoadjuvant chemotherapy, those with advanced disease had a better prognosis in the GC-TLS high-density group than did those in the GC-TLS low-density group. Patients in whom neoadjuvant chemotherapy was effective had more GC-TLSs than those in whom it was less effective. The density of GC-TLSs and the number of tumor-infiltrating CD8
CONCLUSION
CONCLUSIONS
TLS maturation may be important for evaluating the local tumor immune response in patients treated with neoadjuvant chemotherapy for esophageal squamous cell carcinoma. The present results suggest that TLS maturation may be a useful target for predicting the efficacy of immunotherapy, including immune checkpoint inhibitor treatment for esophageal squamous cell carcinoma.
Identifiants
pubmed: 35751038
doi: 10.1186/s12885-022-09777-w
pii: 10.1186/s12885-022-09777-w
pmc: PMC9233387
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
699Informations de copyright
© 2022. The Author(s).
Références
Esophagus. 2017;14(1):1-36
pubmed: 28111535
Oncoimmunology. 2021 Mar 17;10(1):1900635
pubmed: 33796412
BMC Immunol. 2018 Apr 16;19(1):13
pubmed: 29661142
Cancer Sci. 2021 May;112(5):1746-1757
pubmed: 33735485
J Leukoc Biol. 2020 Oct;108(4):1307-1318
pubmed: 32827331
Int J Oral Sci. 2020 Sep 15;12(1):24
pubmed: 32934197
Nat Commun. 2021 Jun 7;12(1):3349
pubmed: 34099645
Front Immunol. 2021 May 26;12:648812
pubmed: 34122408
Lancet. 2013 Feb 2;381(9864):400-12
pubmed: 23374478
Immunity. 2015 Sep 15;43(3):579-90
pubmed: 26341400
Nat Rev Clin Oncol. 2020 Jul;17(7):393-394
pubmed: 32372036
J Surg Res. 2017 Jul;215:74-82
pubmed: 28688665
Nat Rev Cancer. 2019 Jun;19(6):307-325
pubmed: 31092904
Esophagus. 2017;14(1):37-65
pubmed: 28111536
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
BMC Immunol. 2016 Sep 20;17(1):29
pubmed: 27645787
Oncoimmunology. 2020 Feb 17;9(1):1724763
pubmed: 32117589
Cancer Res. 2018 Mar 1;78(5):1308-1320
pubmed: 29279354
Virchows Arch. 2020 Sep;477(3):401-408
pubmed: 32232560
Immunol Rev. 2016 May;271(1):260-75
pubmed: 27088920